# A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

> **NCT00498615** · PHASE3 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 17 (actual)

## Conditions studied

- Raynaud
- Scleroderma

## Interventions

- **DRUG:** Fasudil

## Key facts

- **NCT ID:** NCT00498615
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2014-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498615, "A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00498615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*